Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review
Vaccines · 29.03.2026 · 14 (4) · 308
DOI: 10.3390/vaccines14040308 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 29.03.2026. Verfasst von Fernando M Runzer-Colmenares und 3 weiteren Autor:innen. Beteiligte Einrichtung: CHANGE Research Working Group, Universidad Científica del Sur, Lima 15067, Peru. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Científica del Sur https://ror.org/04xr5we72.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background/Objectives: Vaccination against respiratory viruses—such as respiratory syncytial virus (RSV), pneumococcal disease, influenza, and COVID-19—may reduce the risk of adverse outcomes in older adults with cardiovascular disease. This study conducted a scoping review of the effects of respiratory vaccines in older adults with cardiovascular disease.
Methods
We included studies evaluating adults aged ≥ 60 years with cardiovascular disease who received different types of respiratory vaccines. Eligible designs comprised clinical trials, observational cohort studies, and other relevant studies. Editorials, commentaries, and non-original publications were excluded. A comprehensive and targeted literature search was conducted in PubMed, Scopus, EMBASE, and Web of Science from database inception through January 2026.
Results
A total of 25 studies were included, encompassing 1,782,787 adults aged ≥ 60 years with cardiovascular disease who received various respiratory vaccines. RSV vaccines were associated with a lower incidence of cardiorespiratory hospitalization and stroke among vaccinated individuals. Pneumococcal vaccines showed that sequential dual vaccination strategies were associated with a lower risk of cardiovascular events. Influenza vaccination was associated with improved cardiovascular outcomes, lower mortality, and reduced adverse events. COVID-19 vaccines were associated with reductions in mortality and hospitalizations. These benefits are particularly relevant in an older population with a high burden of comorbidities; therefore, complete vaccination schedules, including booster doses, should be considered a central strategy for prevention and comprehensive management in this high-risk group.
Conclusions
Vaccination against respiratory viruses in older adults with cardiovascular disease demonstrates an overall favorable/acceptable profile of efficacy and safety, with reductions in mortality, hospitalizations, and cardiovascular events, without a significant increase in serious adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CHANGE Research Working Group, Universidad Científica del Sur, Lima 15067, Peru.
- Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad de Aquino Bolivia, Cochabamba, Bolivia.
ORCID-Profile: Fernando M Runzer-Colmenares, Nelson Luis Cahuapaza-Gutierrez, Mariam Miyanay Umeres-Bravo
Förderung
- Universidad Científica del Sur https://ror.org/04xr5we72
Zitieren
APA
Runzer-Colmenares, F. M., Cahuapaza-Gutierrez, N. L., Calderon-Hernandez, C. C., & Umeres-Bravo, M. M. (2026). Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review. Vaccines, 14(4), 308. https://doi.org/10.3390/vaccines14040308
Vancouver
Runzer-Colmenares FM, Cahuapaza-Gutierrez NL, Calderon-Hernandez CC, Umeres-Bravo MM. Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review. Vaccines. 2026;14(4):308. doi:10.3390/vaccines14040308
BibTeX
@article{RunzerColmenares2026,
author = {Runzer-Colmenares, Fernando M and Cahuapaza-Gutierrez, Nelson Luis and Calderon-Hernandez, Cielo Cinthya and Umeres-Bravo, Mariam Miyanay},
title = {Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {4},
pages = {308},
doi = {10.3390/vaccines14040308}
}
EUVIMED